Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: urrutia s. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. Bataller A, et al. Among authors: urrutia s. Leuk Res. 2023 Apr;127:107044. doi: 10.1016/j.leukres.2023.107044. Epub 2023 Feb 15. Leuk Res. 2023. PMID: 36801700 No abstract available.
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Almanza-Huante E, et al. Among authors: urrutia s. Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23. Br J Haematol. 2023. PMID: 36951293 No abstract available.
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Leukemia. 2023 Jun;37(6):1397-1400. doi: 10.1038/s41375-023-01899-9. Epub 2023 Apr 25. Leukemia. 2023. PMID: 37185307 No abstract available.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Am J Hematol. 2023 Oct;98(10):E281-E284. doi: 10.1002/ajh.27043. Epub 2023 Jul 29. Am J Hematol. 2023. PMID: 37515433
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Among authors: urrutia s. Clin Cancer Res. 2024 Apr 1;30(7):1319-1326. doi: 10.1158/1078-0432.CCR-23-2860. Clin Cancer Res. 2024. PMID: 38300723
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Among authors: urrutia s. Blood Adv. 2024 Mar 21:bloodadvances.2024012565. doi: 10.1182/bloodadvances.2024012565. Online ahead of print. Blood Adv. 2024. PMID: 38513082
50 results